Rucaparib (phosphate)

CAT: 0804-HY-10617-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10617-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].
CAS Number
[459868-92-9]
Product Name Alternative
AG-014699 (phosphate) ; PF-01367338 (phosphate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PARP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Rucaparib-phosphate.html
Purity
99.76
Solubility
DMSO : ≥ 33 mg/mL|H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=P(O)(O)O.FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1
Molecular Formula
C19H21FN3O5P
Molecular Weight
421.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Thomas HD, et al. Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther, 2007, 6 (3), 945-956.|[2]Hunter JE, et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31 (2), 251-264.|[3]Daniel RA, et al. Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res, 2009, 15 (4), 1241-1249.|[4]Matt Shirley, et al. Rucaparib: A Review in Ovarian Cancer. Target Oncol. 2019 Apr;14 (2) :237-246.|[5]Jianneng Li, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. 2021 May 26;13 (595) :eabe8226.|[6]J Murray, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014 Apr 15;110 (8) :1977-84.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PARP1; PARP2; PARP3
Citation 01
Analyst. 2018 May 29;143 (11) :2501-2507.|Biochem Biophys Res Commun. 28 September 2021.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Nat Cell Biol. 2024 Sep;26 (9) :1545-1557.|Patent. US20200078369A1|Patent. US20200129476A1|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Sens Actuators B Chem. 2018 Nov 10; 273:1047-1053. |Sens Actuators B Chem. 2018, 259: 565-572.|Aging (Albany NY) . 2021 Jan 20;13 (3) :4242-4257.|Am J Cancer Res. 2020 Aug 1;10 (8) :2649-2676.|Am J Cancer Res. 2024 Jan 15;14 (1) :378-389.|bioRxiv. 2023 Feb 6:2023.02.06.527366.|bioRxiv. 2023 Feb 7:2023.02.07.527369.|bioRxiv. 2024 Jul 10:2024.07.09.602803.|bioRxiv. 2024 Sep 19:2024.09.19.613696.|BMC Cancer. 2022 Mar 23;22 (1) :312.|Cancers (Basel) . 2024 Nov 5;16 (22) :3728.|Clin Cancer Res. 2017 Feb 15;23 (4) :1001-1011. |DNA Repair. 2019 Jan:73:64-70.|Eur J Nucl Med Mol Imaging. 2024 Nov;51 (13) :4099-4110.|FASEB J. 2022 Jul;36 (7) :e22418.|Front Oncol. 2021 Jul 9:11:681441.|Gene. 2020 Oct 30;759:145000.|Genes Dis. 2023 Apr 12;11 (2) :993-1008.|Int J Mol Sci. 2020 Feb 11;21 (4) :1185.|JCI Insight. 2023 Nov 8;8 (21) :e165268.|Mol Cancer Ther. 2024 Oct 1;23 (10) :1404-1417.|Mol Cancer Ther. 2025 Jul 2.|Nat Commun. 2025 Jun 2;16 (1) :5126.|Nat Methods. 2023 Sep;20 (9) :1388-1399.|Neoplasia. 2025 May:63:101152.|Neurooncol Adv. 2023 Feb 10;5 (1) :vdad010.|Patent. US20180263995A1.|Patent. US20180362972A1.|Research Square Preprint. 2024 Nov 06.|Research Square Print. September 20th, 2022.|Research Square Print. September 22nd, 2022.|Sci Adv. 2022 Feb 18;8 (7) :eabl9794.|Sci Adv. Sci Adv. 2025 Apr 25;11 (17) :eadu0847.|Sci Immunol. 2024 Mar 15;9 (93) :eadj7238.|Sci Transl Med. 2021 May 26;13 (595) :eabe8226.|Talanta. 2018 Apr 1:180:127-132.|Theranostics. 2020 Jul 25;10 (21) :9477-9494.

Related Products

CatalogName
HY-10617A-01Rucaparib
HY-10617ASRucaparib-d8
HY-10617AR-01Rucaparib (Standard)
HY-10617BRucaparib (hydrochloride)
HY-10617DRucaparib (acetate)
HY-102003ARucaparib (camsylate)
HY-10617CRucaparib (tartrate)
HY-102003-01Rucaparib (monocamsylate)
HY-Y1322-01Triphenyl phosphate
HY-B1067BAntazoline (phosphate)

Alternative Products

CatalogName
MBS3604548-01Rucaparib phosphate
TBI3321-5MGRucaparib phosphate, PARP inhibitor
A10045-1Rucaparib (AG-014699) phosphate 1mg
A10045-5Rucaparib (AG-014699) phosphate 5mg
A10045-25Rucaparib (AG-014699) phosphate 25mg
A10045-200Rucaparib (AG-014699) phosphate 200mg
A10045-2Rucaparib (AG-014699) phosphate 2mg
A10045-10Rucaparib (AG-014699) phosphate 10mg
A10045-50Rucaparib (AG-014699) phosphate 50mg
A10045-100Rucaparib (AG-014699) phosphate 100mg

Popular Products